Free Rheumatology CME

  • FREE

    Podcast Series on Herpes Zoster Prevention: Pearls for Clinicians Managing Patients With Immune-mediated Diseases

    Shingles, also called herpes zoster (HZ), is a painful rash that develops due to reactivation of the varicella zoster virus, which causes chicken pox. Approximately 1 in 3 individuals in the United States will develop shingles during their lifetime, with adults over 50 years of age and immunocompromised individuals being at highest risk. Recent developments in HZ prevention include a new recombinant zoster vaccine, which is now recommended as the preferred shingles vaccine in updated guidelines from the Advisory Committee on Immunization Practices (ACIP). Effective prevention and risk management strategies are particularly important for patients with immune-mediated diseases. In this CME podcast series, experts will review the clinical aspects and primary risk factors for HZ, discuss optimized use of vaccines for at-risk populations, and provide guidance on effective patient education strategies to enhance vaccine uptake.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Vindico Medical Education
    • Format: Podcast
  • FREE

    Best of FSR Annual Meeting 2020: Immunology Bootcamp – Immunology 101

    The hallmarks of immune-mediated inflammatory diseases (IMIDs) result from the intricate interplay of cells, cytokines, and other components of the immune system. Similar pathology underlies related rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus, and giant cell arteritis. Understanding the immunopathology of these diseases is essential to understanding the mechanisms of action through which different medications exert their effects. Another emerging trend in rheumatology is the identification and management of immune-related adverse events associated with new cancer immunotherapies; however, providers lack experience in managing these conditions. In this educational activity, Dr. Leonard Calabrese discusses the latest on the pathogenesis and treatments of IMIDs.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Vindico Medical Education
    • Format: Video
  • FREE

    Best of FSR Annual Meeting 2020: Immunology Bootcamp – Advances in Targeted Therapies

    The hallmarks of immune-mediated inflammatory diseases (IMIDs) result from the intricate interplay of cells, cytokines, and other components of the immune system. Similar pathology underlies related rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus, and giant cell arteritis. Understanding the immunopathology of these diseases is essential to understanding the mechanisms of action through which different medications exert their effects. Another emerging trend in rheumatology is the identification and management of immune-related adverse events associated with new cancer immunotherapies; however, providers lack experience in managing these conditions. Biosimilars are another possible new treatment option in IMIDs. In this educational activity, Dr. Vibeke Strand discusses the latest on the pathogenesis and treatments of IMIDs.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: Vindico Medical Education
    • Format: Video
  • FREE

    “Best of” Second Annual Rheumatology Summit for Fellows: Optimizing Therapy While Reducing Risk

    Rheumatology has seen rapid growth in both basic science and clinical understanding in recent years, much of which is inadequately addressed in medical training programs. There has also been an increase in the number of rheumatology fellowship programs to meet the increasing demand. To address gaps in knowledge and training in medical training programs regarding the management of patients with rheumatic disease, Vindico Medical Education held a day-long virtual educational activity for rheumatology fellows, led by an interdisciplinary panel of experts, addressing the treatment of patients with rheumatic disease as well as the management of associated complications and comorbidities. This “Best of” program provides highlighted presentations from that program.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.5
    • CME credits awarded by: Vindico Medical Education
    • Format: Video
  • FREE

    Healio Free Rheumatology CME

    Find out what over 50,000 of your colleagues already know. Earn credits faster and easier with Healio CME.

    See full details chevron_right
    • Cost: Free
    • Credit hours: Varies
  • FREE

    Immune-Mediated Inflammatory Disease Curbside Consults: Psoriasis – New and Emerging Options for Disease Management

    In this Curbside Consult video, Drs. Leonard Calabrese and Anthony Fernandez discuss new and emerging treatment options for a patient with persistent moderate psoriasis despite ongoing therapy.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .25
    • CME credits awarded by: Vindico Medical Education
  • FREE

    Immune-Mediated Inflammatory Disease Curbside Consults: RA – What to Do After TNF Failure?

    In this Curbside Consult video, Drs. Leonard Calabrese and Stanley Cohen discuss strategies for managing RA in a patient after loss of response to first-line TNF inhibitor therapy.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .25
    • CME credits awarded by: Vindico Medical Education
  • FREE

    Immune-Mediated Inflammatory Disease Curbside Consults: Updates in Non-TNF Biologic Options for Patients With IBD

    In this Curbside Consult video, Drs. Miguel Regueiro and Benjamin Cohen discuss the clinical evidence to support emerging treatment options for a patient with biologic-naïve Crohn’s disease.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .25
    • CME credits awarded by: Vindico Medical Education
    • Format: Video
  • FREE

    Systemic lupus erythematosus: therapeutic updates and optimizing treatment

    Activity Description / Statement of Need:

    Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous etiologies and clinical phenotypes, all with varying degrees of severity. Although the precise mechanism of SLE-related autoimmunity is still uncertain, strong evidence implicates a combination of genetic and environmental factors in the disease pathology. For most of the medical community, the primary challenges of SLE management stem from the disease heterogeneity, which leads to difficulty in diagnosing, treating, and monitoring.

    Evidence suggests that there are a number of gaps in the treatment of lupus stemming from a suboptimal patient-provider relationship. Suggested remedies include a: patient-centered approach to care, improvement of disease awareness, focus on taking adequate time to provide disease and treatment information as well as treatment adherence, and sensitivity to patient concerns.

    Target Audience:

    Rheumatologists and primary care physicians and other specialists who care for patients with SLE (e.g., dermatologists, nephrologists, OBGYNs); physician assistants, nurse practitioners, and pharmacists who practice in rheumatology; and any other HCPs with an interest in or who clinically encounter patients with SLE.

    By the end of the session the participant will be able to:

    • Describe the pathophysiology of systemic lupus erythematosus (SLE), with a focus on the factors affecting disease progression, remission, and therapeutic mechanisms
    • Recall identification of SLE disease activity, flares, and treatment goals, both short- and long-term
    • Describe the influence of disease activity and corticosteroid use on organ damage in SLE
    • Evaluate available and emerging therapeutic options for SLE, individualizing treatment regimens based on patient and disease characteristics
    • Discuss the role and importance of patient-provider communication in charting a course of optimal treatment
    See full details chevron_right
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 12/17/2020
    • Expiration of CME credit: 12/17/2022
  • FREE

    Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?

    Biosimilar drugs are products meant to be similar in quality, safety, and efficacy to an already licensed reference biotherapeutic product. Whereas generics are virtually identical replicas of conventional medications, biosimilars are not the same as the original product – a practically unavoidable outcome because of the considerably large molecular structure that biologics mimic. The literature suggests that learning activities focused on the evolving landscape of biosimilars, which are germane to the therapeutic area because of their potential role in cost containment. Both the FDA and medical literature independently affirm the need for clinician education on biosimilars, including:  comparative efficacy; adverse event rates and management (potential concerns have included immunogenicity); regulatory guidance on interchangeability and substitution – including prescribers retaining some degree of ability to intervene in a product’s substitution at the dispensing stage; and cost considerations.

    Target Audience:

    The following healthcare professionals: Rheumatologists, gastroenterologists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with the inflammatory disease states covered by this activity.

    By the end of the session the participant will be able to:

    • Describe biosimilar drugs, how they differ from generic drugs, the FDA process for their approval.
    • Describe practical considerations the clinician needs when determining whether to consider when deciding whether substituting or allowing the substitution of a biosimilar medication for its reference medication, and apply them to patient case(s).
    • Describe how biosimilars for inflammatory health conditions are impacting the treatment landscape with respect to number of treatment options, affordability, and safety considerations.
    • Identify the currently available and emerging pharmacotherapeutic treatments for management of inflammatory health conditions and apply them to patient cases using evidence-based medicine.
    • Describe strategies for helping patients understand the implications of using biosimilars.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/25/2020
    • Expiration of CME credit: 06/25/2022